Absence of peripapillary retinal nerve-fiber-layer thinning in combined antiretroviral therapy-treated, well-sustained aviremic persons living with HIV

Cédric Lamirel, Nadia Valin, Julien Savatovsky, François-Xavier Lescure, Anne-Sophie Alonso, Philippe Girard, Jean-Paul Vincensini, Pierre-Marie Girard, Laurence Salomon, Isabelle Cochereau, Antoine Moulignier

1 Département d’Ophtalmologie, Fondation Adolphe de Rothschild, Paris, France, 2 Service d’Ophtalmologie, APHP, Hôpital Bichat–Claude-Bernard, Paris, France, 3 Service des Maladies Infectieuses et Tropicales, APHP, Hôpital Saint-Antoine, Paris, France, 4 Service d’Imagerie Médicale, Fondation Adolphe de Rothschild, Paris, France, 5 Service des Maladies Infectieuses et Tropicales, APHP, Hôpital Bichat–Claude-Bernard Paris, France, 6 Unité de Recherche Clinique, Fondation Adolphe de Rothschild, Paris, France, 7 Service de Pneumologie, Institut Mutualiste Montsouris, Paris, France, 8 Sorbonne Paris Cité, Université Paris Diderot, Paris, France, 9 Service de Neurologie, Fondation Adolphe de Rothschild, Paris, France

* clamirel@for.paris

Abstract

Purpose
To compare peripapillary retinal nerve-fiber-layer (pRNFL) thickness, total retina macular volume, and ganglion-cell-layer (GCL) macular volume and thickness between persons living with HIV (PLHIVs) with well-controlled infections and good immune recovery, and sex- and age-matched HIV-uninfected controls (HUCs).

Methods
This prospective cross-sectional study (www.clinicaltrials.gov identifier: NCT02003989) included 56 PLHIVs, infected for ≥10 [median 20.2] years and with sustained plasma HIV-load suppression on combined antiretroviral therapy (cART) for ≥5 years, and 56 matched HUCs. Participants underwent spectral-domain optical coherence tomography (SD-OCT) with thorough ophthalmological examinations and brain magnetic resonance imaging (MRI). Their overall and quadrant pRNFL thicknesses, total macular volumes, and GCL macular volumes and thicknesses were compared. Cerebral small-vessel diseases (CSVD) complied with STRIVE criteria.

Results
Median [interquartile range, IQR] ages of PLHIVs and HUCs, respectively, were 52 [46–60] and 52 [44–60] years. Median [IQR] PLHIVs’ nadir CD4+ T-cell count and current CD4/CD8 T-cell ratio were 249/μL [158–350] and 0.95 [0.67–1.10], respectively; HIV-seropositivity duration was 20.2 [15.9–24.5] years; cART duration was 16.8 [12.6–18.6] years; and
salmon and i. cochereau have no disclosures to report. f.-x. lescure has received funding for board membership from gilead sciences and MSD france; for lectures from BioMérieux, Gilead sciences and MSD france; and to travel to meetings from Gilead sciences, MSD france, Astellas and Eumedica. P. girard has received support to travel to meetings and accommodations from Bayer and Leo Pharma. P.-M. girard has received honoraria for participation on international advisory boards from Gilead, VIIV Healthcare and Abbvie, and honoraria for speaking engagements from Janssen and BMS. A. moulinier has received research support from the Association Nationale de Recherche sur le SIDA (ANRS); funding for lectures from Biogen Idec and Norvatis, and to travel to meetings from Biogen Idec and Teva Pharma. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

aviremia duration was 11.4 [7.8–13.6] years. No significant between-group pRNFL thickness, total macular volume, macular GCL-volume and -thickness differences were found. MRI-detected CSVD in 21 (38%) PLHIVs and 14 (25%) HUCs was associated with overall thinner pRNFLs, and smaller total retina and GCL macular volumes, independently of HIV status.

Conclusions
SD-OCT could not detect pRNFL thinning or macular GCL-volume reduction in well-sustained, aviremic, cART-treated PLHIVs who achieved good immune recovery. However, CSVD was associated with thinner pRNFLs and GCLs, independently of HIV status.

Introduction
Combined antiretroviral therapy (cART) ensures human immunodeficiency virus (HIV) suppression and immunological recovery in a majority of persons living with HIV (PLHIVs), dramatically improving life expectancy [1,2]. As a consequence, cART-treated PLHIVs are exposed to chronic HIV-infection that may be deleterious to neural tissues [3,4]. Hence, despite well-sustained immunovirological control on cART, subtle structural and functional retinal abnormalities, described as HIV-associated neuroretinal disorder (HIV–NRD) and milder forms of HIV-associated neurocognitive disorders (HAND) are still frequent in PLHIVs [5,6]. In addition, aging PLHIVs’ life expectancy persistently lags behind that of the general population, predominantly because of their heightened risk for age-related comorbidities, to which they might be more vulnerable [7,8]. Among those age-related comorbidities, magnetic resonance imaging (MRI)-detected [9] cerebral small-vessel disease (CSVD) prevalence is doubled in cART-treated, immunovirologically well-controlled, middle-aged PLHIVs compared to age-matched HIV-uninfected individuals [10]. The best-known MRI characteristics of CSVD are white-matter hyperintensities (WMHs) of presumed vascular origin, silent brain infarcts and cerebral microbleeds [11]. To better characterize and differentiate CSVD-surrogate WMHs from WMHs of other origins, the STandards for ReportIng Vascular changes on Euroimaging (STRIVE) criteria, developed to standardize reading of CSVD neuroimages, were applied [9]. The results of several studies [12–15] documented the cognitive impact of CSVD-surrogate WMHs on cART-treated PLHIVs with long-term virus suppression, leading to the recent paradigm of vascular-driven, milder HAND forms [16].

The concept of the retina being an anatomical and functional central nervous system surrogate is increasingly recognized [17]. Notably, cerebral and retinal arterioles share similar anatomy, physiology and embryology, and evidence supports an association between retinal vessel changes and CSVD [18]. Optical coherence tomography (OCT) is an in situ micrometer-scale imaging technique that closely correlates with histological retinal structures [19,20]. Indeed, OCT accurately and reproducibly measures the peripapillary retinal nerve-fiber–layer (pRNFL) thickness that reflects the number of ganglion-cell axons leaving the retina to form the optic nerve. OCT can also evaluate the thickness of the ganglion-cell–layer (GCL) macula that contains mostly ganglion-cell bodies.

Spectral-domain (SD)-OCT detected significant pRNFL thinning in severely immunodeficient PLHIVs (i.e., CD4+ T-cell count <100/μL) [21–23]. In PLHIVs, GCL thinning has been associated with HAND [24]. However, those findings were heterogeneous, and all studies were hampered by the absence of brain and orbit MRI to exclude optic neuropathy or CSVD (Table 1). Indeed, pRNFL thinning has been associated with optic neuropathies [25], and CSVD-surrogate WMHs in the general population [26,27] and HIV-infected children [28].
Table 1. Reported peripapillary retinal nerve-fiber–layer (pRNFL) thicknesses in PLHIV or HUC participants.

| Ref. Sample | Age (y) | Years HIV+ | Years on cART | CD4+ T-cell (cells/μL) | CD4/CD8 T-cell ratio | Current pVL log_{10} | % pVL undetectable | Years of aviremia | OCT Overall | Superior | Inferior | Nasal | Temporal |
|-------------|---------|------------|---------------|------------------------|----------------------|---------------------|-------------------|------------------|-------------|-----------|---------|-------|---------|
| [5]         | 93 HIV+ | 53.5±1.5   | 14.5±0.8      | 12±1                   | 0.75±0.25            | 1.0±0.2            | 98.0±2.0         | 10.2±0.2        | SD          | 102.0±11.3| 125.5±20.2| 131.1±16.8| 78.5±15.3| 72.9±13.5|
|             | 63 HIV– | 52±1.5     |               |                        |                      |                    |                  |                 |             | 100.0±10.1| 125.4±17.3| 128.1±15.8| 74.2±16.0| 72.4±12.5|
| [21]        | 25 HIV+ | 42.6±1.1   | 7.2±0.8       | 5.6±0.9                | 301.0±31.1           | 50±41.3            | NR                | NR              | NR          | 107.3±11.0*| 133.9±21.1**| 138.0±16.5**| 87.4±17.0| 69.7±13.0|
|             | 26 HIV+ | 43.5±1.5   | 8.4±1.3       | 5.9±1.1                | 28.3±4.6             | 219.9±49.19        | NR                | NR              | NR          | 96.1±21.3*| 119.4±32.6| 122.9±32.2*| 76.7±27.6| 65.7±12.8|
|             | 22 HIV+ | 43.2±1.5   | 8.4±1.3       | 5.9±1.1                | 28.3±4.6             | 219.9±49.19        | NR                | NR              | NR          | 107.2±12.7| 129.4±16.7| 136.8±16.7| 89.4±22.3| 71.4±12.4|
| [22]        | 12 HIV+ | NR         | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 97.2±12.8| NR         | NR      | NR       |
|             | 10 HIV+ | NR         | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 74.6±17.4**| NR         | NR       | NR       |
| [23]        | 18 HIV+ | 41.7±1.5   | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 103.3±9.3| 127.5±17.6| 138.6±14.3| 74.6±15.4| 73.2±14.7|
|             | 25 HIV+ | 41.6±1.5   | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 90.1±12.5*| 110.3±20.7*| 112.4±22.9*| 72.2±12.4| 65.2±16.9*|
|             | 22 HIV+ | 38.2±1.5   | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 103.3±8.5| 122.7±12.7| 137.2±17.5| 78.3±15.1| 75.9±17.7|
| [24]        | 69 HIV+ | 53.1±7.3   | 14.5±1.5      | 17.8±14.5              | 676.1±306            | NR                  | NR                | NR              | NR          | 97.6±8.6| NR         | NR      | NR       |
|             | 64 HIV+ | 51.6±7.5   | 14.5±1.5      | 17.8±14.5              | 676.1±306            | NR                  | NR                | NR              | NR          | 95.2±13.8| NR         | NR      | 68.5±14.1|
| [42]        | 33 HIV+ | 12.1±1.5   | 10.7±7.1      | 760±80                 | 82%                  | NR                  | NR                | NR              | NR          | 112.1±15.8| NR         | NR      | NR       |
|             | 36 HIV+ | 13.7±1.5   | 10.7±7.1      | 760±80                 | 82%                  | NR                  | NR                | NR              | NR          | 112.2±9.5| NR         | NR      | NR       |
| [43]        | 225 HIV+| 41.2±0.5   | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 100.7±12.0| 135.1±21.0| 135.6±21.0| 91.1±22.5| 73.1±13.5|
|             | 203 HIV+| 41.9±0.6   | NR            | NR                      | NR                   | NR                  | NR                | NR              | NR          | 108.7±12.8| 132.2±21.4| 137.9±21.4| 88.4±21.4| 72.5±12.8|

(Continued)
We undertook this concurrent cohort study to investigate pRNFL and GCL thicknesses in PLHIVs with well-sustained, cART-controlled, immunovirological parameters and HIV-uninfected controls (HUCs). Because we wanted to examine the role of chronic HIV infection itself, we selected PLHIVs with cART-sustained, immunovirological control for at least 5 years, without hepatitis C virus (HCV) infection, past or ongoing acquired immune deficiency syndrome (AIDS)-defining neurological events (ADNEs), and/or alcohol or illicit drug abuse.

### Methods

#### Ethics approval

This study, approved by the CPP Île-de-France VI Ethics Committee, adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants.

---

**Table 1. (Continued)**

| Ref | Sample | Age (y) | Years HIV+ | Years on cART | CD4+ T-cell (cells/μL) Nadir | CD4+ T-cell ratio | Current pVL log10 | % pVL undetectable | Years of aviremia | OCT | pRNFL thickness (μm) |
|-----|--------|---------|------------|---------------|-----------------------------|-------------------|-----------------|-----------------|----------------|-----|---------------------|
|     | HIV+   |         |            |               |                             |                   |                 |                 |                |     | Overall*             |
| 19  | HIV+   | 53.9 [44–73] | 17.0       | NR            | >200                        | NR                | ≤1.7            | NR              | NR             | SD  | 92.7±14.4           |
| 28  | HIV+   | 55.1 [41–85] | 18.2       | NR            | <200                        | NR                | ≤1.7            | NR              | NR             | NR  | 91.0±11.1           |
| 57  | HIV−   | 56.2 [28–84] |           |               |                             |                   |                 |                 |                | NR  | 70.7±16.6           |
| [46] | HIV+   | 43.12±7.80 | 7.8        | 6.2           | 162.02±175.69               | 355.48±267.69     | NR              | NR              | NR             | TD  | 99.9±13.7           |
| 22  | HIV−   | 43.27±12.15|           |               |                             |                   |                 |                 |                |     | 105.2±9.0           |
| [60] | HIV+   | 37.3 [17–75] | NR         | NR            | NR                          | 426 [36–954]      | 5.2 [1–6.1]     | 55.6%           | SD             |     | 100.5±9.5           |
| 47  | HIV−   | 39.4 [20–38] |           |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
|     |        |          |            |               |                             |                   |                 |                 |                |     | 127.5±13.1          |
| 56  | HIV+   | 51.5 [45.5–59.5] | 20.2 [15.9–24.5] | 16.8 [12.6–18.6] | 249 [158–350] | 691 [526–1053] | 0.95 [0.67–1.10] | 1.0 [1.0–1.0] | 100% | 11.4 [7.8–13.6] | SD | 99.5±9.6 |
|     | HIV−   | 52.0 [44.0–60.0] | 20.2 [15.9–24.5] | 16.8 [12.6–18.6] | 249 [158–350] | 691 [526–1053] | 0.95 [0.67–1.10] | 1.0 [1.0–1.0] | 100% | 11.4 [7.8–13.6] | SD | 99.5±9.6 |

Values are expressed as mean±standard deviation, or median [interquartile range] or [range].

* Overall values are the averages each individual 4 quadrants.

PLHIVs: human immunodeficiency virus-infected participants; HUCs: HIV-uninfected controls; OCT: optical coherence tomography; TD: time-domain; SD: spectral-domain; pVL: plasma HIV load; IQR: interquartile range; NR: not reported; NCI: no cognitive impairment. CI: cognitive impairment.

* Statistically significant (p<0.05) difference between HIV+ subjects and HIV− controls.

**Statistically significant (p<0.05) difference between high and low CD4+ T-cell nadirs for HIV+ patients.

https://doi.org/10.1371/journal.pone.0229977.t001
Study population
In this cross-sectional study (NCT02003989), we prospectively included PLHIVs followed in two Infectious Diseases Departments in University Hospitals, caring for about 8,000 PLHIVs in the Paris area (France). Inclusion criteria were: (1) HIV seropositivity known for ≥10 years; sustained CD4+ T-cell count ≥350/μL and plasma HIV load (plVL) <20 copies/mL for ≥5 years on cART. plVL was quantified using the Amplicor monitor assay (Cobas 2.0, Roche Diagnostics, Basel, Switzerland), which has a lower detection limit of 20 HIV-1 RNA copies/mL. Exclusion criteria were: (1) transient low-level viremias 20 but ≤200 copies/mL (viral blip) once within the previous 5 years; (2) history/concomitant ocular trauma or diseases; (3) family history of glaucoma; (4) prior/current treatment with drugs associated with toxic optic neuropathy or retinopathy; (5) prior/current neurological/psychiatric disorders, including ADNE; (6) prior/current diabetes mellitus; (7) prior/current alcohol or illicit substance abuse (with the exception of occasional cannabis use); (8) HCV infection. Cognitive decay was not sought prior to inclusion and was not an exclusion criterion.

Age (±5 years)- and sex-matched (1:1) HUCs were selected on a voluntary basis; exclusion criteria were the same as for PLHIVs. The absence of HIV infection was confirmed by ELISA or rapid HIV test.

All participants underwent the same comprehensive neurological and ophthalmological examinations. All SD-OCT were obtained with a Spectralis OCT, which generates four sectoral pRNFL thicknesses and an overall value that is the average of the four quadrants, using the new Nsite Axonal Analytics software (Heidelberg Engineering GmbH, Heidelberg, Germany). Overall and sectoral pRNFL thicknesses were recorded for each eye. The total retinal macular volume was calculated with the Heidelberg software using the Early Treatment for Diabetic Retinopathy Study (ETDRS) grid. We used the Iowa Reference Algorithm to segment the GCL and calculated the GCL thickness for each of the 9 ETDRS-grid subfields and the total GCL macular volume within the ETDRS grid (S1 Fig) [29–31]. Cognition was assessed using the Montreal Cognitive Assessment (MoCA), known to be an adequate clinical and ecological screening tool for PLHIVs [32,33]. 3-Tesla brain MRI and orbit images (Philips Healthcare, Best, The Netherlands) were analyzed by one neuroradiologist (J.S.) blinded to all parameters. CSVD was defined according to the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) Criteria [9].

Main outcome measure and estimated number of participants
The main outcome measure was the overall pRNFL thickness. Previous studies found a standard deviation of ~9 μm for it with the OCT machine used herein [34]. With that standard deviation, a unilateral 5% alpha-risk and 95% power, we estimated that 50 participants in each group would be sufficient to detect ≥7-μm pRNFL thinning in PLHIVs compared to HUCs.

Statistical analyses
Only one eye of each participant was randomly selected for analysis. The non-parametric Mann-Whitney U-test and chi² or Fisher’s exact test were used as appropriate to compare groups. Analysis of variance (ANOVA) of repeated measures was used to detect differences among the different pRNFL quadrants and among the different GCL ETDRS-grid subfields.

Linear-regression models were used to test associations between OCT measurements (outcome variables: overall and temporal pRNFL thicknesses, total retinal macular volumes, GCL macular volumes) and visual function measurements, axial length and age (predictor variables). HIV status was included in all these linear-regression models to test a possible HIV effect on an association.
For the PLHIV group, associations between overall and temporal pRNFL thicknesses, total retinal macular volumes, GCL macular volumes (outcome variables) and duration of HIV infection (predictor variable) were tested with a multivariate model including age as a covariate. Univariate regression analyses were used to identify associations between PLHIVs’ overall and temporal pRNFL thicknesses, total retinal macular volumes or GCL macular volumes (outcome variables) and CD4+ T-cell nadirs (predictor variable).

Significance was defined as $p < 0.05$. All analyses were computed with Statistica software (Statsoft, Inc, Maison Alfort, France) and no statistical correction was made for multiple comparisons.

**Results**

Among 71 PLHIVs initially included, 15 were secondarily excluded because of bilateral glaucoma ($n = 1$), bilateral high ametropia ($n = 6$), previous bilateral ocular surgery ($n = 3$), alcoholism ($n = 1$), diabetes ($n = 2$), HCV infection ($n = 1$) or missing MRI ($n = 1$). Among 65 HUCs initially included, nine were secondarily excluded because of bilateral high ametropia ($n = 4$), bilateral glaucoma ($n = 1$), diabetes ($n = 1$), HCV infection ($n = 1$), missing MRI ($n = 1$) or MRI-detected meningioma ($n = 1$). A total of 56 PLHIV-eyes and 56 HUC-eyes were included in the statistical analyses. Participants’ characteristics are summarized in Table 2.

The median CD4+ T-cell nadir was 249 cells/μL and median CD4/CD8 T-cell ratio was 0.95. All PLHIVs had pVLs <20 copies/mL for 11±4 years and achieved immune recovery on cART, including aviremia and CD4+ T-cell counts >350 cells/μL for 10±3 years.

pRNFL thicknesses, total retinal macular volumes and GCL macular volumes and thicknesses (Table 3) did not differ between PLHIVs and HUCs. These analyses were repeated using the other eye when both eyes were assessable and the results were comparable (S1 Table). Potential confounding factors (axial length, spherical equivalent and Optical Quality Analyzing System (OQAS)-assessed media opacity) were comparable for PLHIVs and HUCs.

Among the functional parameters (Table 3), high contrast VA, low contrast VA and color vision were comparable for PLHIVs and HUCs. However, visual field mean deviations (MDs) and intraocular pressure (IOP) differed significantly, being slightly lower for PLHIVs than HUCs but still within normal limits.

Associations between structural measures and other variables are reported in Table 4. Age was associated with overall pRNFL thickness, GCL macular volume and total retinal macular volume, with HIV status having no significant effect (Fig 1). Among the PLHIVs, no significant association between structural measures and HIV-infection duration or CD4+ T-cell nadir was found (Table 4, Fig 2).

MRIs did not reveal a lesion that could cause optic neuropathy or trans-synaptic retrograde degeneration within the optic nerves. MRI detected CSVD in 21 (38%) PLHIVs and 14 (25%) HUCs ($p = 0.15$); it mainly reflected WMHs of presumed vascular origin (21 PLHIVs versus 12 HUCs, $p = 0.06$). Documented CSVD was associated with overall thinner pRNFLs, smaller whole retinal macular volumes and smaller GCL macular volumes for all participants, with HIV status having no significant effect (Fig 3, S1 Table).

**Discussion**

Our results showed that overall and 4-quadrant (localized) pRNFLs, total retinal macular volumes, GCL macular volumes and EDTRS-grid–defined GCL regional thicknesses were not smaller in long-term–sustained, immunovirologically controlled PLHIVs compared to age- and sex-matched HUCs.
Table 2. Epidemiological, clinical, biological and radiological characteristics of PLHIV and HUC participants.

| Characteristic                          | PLHIVs (n = 56) | HUCs (n = 56) | p value |
|----------------------------------------|-----------------|---------------|---------|
| **Demographic**                        |                 |               |         |
| Age at enrollment, y                   | 51.5 [45.5–59.5] | 52.0 [44.0–60.0] | 0.96<sup>b</sup> |
| Age at HIV diagnosis, y                | 32.8 [26.6–39.9] | –             |         |
| Caucasian, n (%)                       | 56 (100%)       | 56 (100%)     |         |
| Male, n (%)                            | 49 (87.5)       | 49 (87.5)     | 1.00<sup>c</sup> |
| Education ≥12 y, n (%)                 | 44 (78.6)       | 43 (76.8)     | 0.82<sup>b</sup> |
| MoCA score                             | 27 [25–29]      | 28 [26–29]    | 0.15<sup>c</sup> |
| **Smoking status, n (%)**              |                 |               |         |
| Current smoker                         | 14 (25)         | 21 (37.5)     | <0.05<sup>c</sup> |
| Former smoker                          | 20 (35.7)       | 8 (14.3)      |         |
| Never smoker                           | 22 (39.3)       | 25 (44.6)     |         |
| **Alcohol consumption**                |                 |               |         |
| Never, n (%)                           | 6 (10.7)        | 8 (14.3)      |         |
| ≤3 glasses/week, n (%)                 | 50 (89.3)       | 44 (78.6)     |         |
| ≤2 glasses/day, n (%)                  | 0               | 2 (3.4)       |         |
| **Comorbidities**                      |                 |               |         |
| Controlled hypertension, n (%)         | 14 (25)         | 4 (7.1)       | 0.01<sup>c</sup> |
| Cardiovascular disease, n (%)          | 8 (14.3)        | 0             | <0.01<sup>d</sup> |
| Renal disease                          | 0               | 0             |         |
| Body mass index (kg/height<sup>2</sup>) | 22.5 [20.8–25.0] | NR           |         |
| Frailty status ≥3                      | 0               | 0             |         |
| **Brain and orbit MRI**                |                 |               |         |
| Cerebral small-vessel disease, n (%)   | 21 (37.5)       | 14 (25)       | 0.15<sup>c</sup> |
| White matter hyperintensities, n (%)  | 21 (37.5)       | 12 (21.4)     | 0.06<sup>c</sup> |
| Cerebral microbleeds, n (%)            | 2 (3.6)         | 4 (7.1)       | 0.68<sup>d</sup> |
| Silent brain infarcts, n (%)           | 1 (1.8)         | 1 (1.8)       | 1.00<sup>d</sup> |
| **HIV-transmission route**             |                 |               |         |
| Homosexual/bisexual, n (%)             | 42 (75)         | –             |         |
| Heterosexual, n (%)                    | 10 (17.9)       | –             |         |
| IVDU, n (%)                            | 3 (5.4)         | –             |         |
| Unknown, n (%)                         | 1 (1.8)         | –             |         |
| CDC stages A/B/C, n (%)                | 31 (55)/12 (22)/13 (23) | – |         |
| HIV-seropositivity duration, y         | 20.2 [15.9–24.5] | – |         |
| AIDS duration, y (n = 10)              | 17.1 [7.5–23.9] | – |         |
| **Antiretroviral treatment**           |                 |               |         |
| Duration, y                            | 16.8 [12.6–18.6] | – |         |
| Treatment regimens, n                  | 4 [3–8]         | –             |         |
| **Immunology/virology**                |                 |               |         |
| Nadir CD4+ T-cell count (cells/μL)     | 249 [158–350]   | –             |         |
| Current CD4+ T-cell count (cells/μL)   | 691 [526–1053]  | –             |         |
| Current CD4+ T-cell count (cells/μL)   | 788 [664–1048]  | –             |         |
| Current CD4/CD8 T-cell ratio           | 0.95 [0.67–1.10] | – |         |
| Duration of CD4+ T-cell count ≥350 cells/μL, y | 11.0 [7.9–14.3] | – |         |
| Current HIV pVL (log<sub>10</sub>)     | 1.0 [1.0–1.0]   | –             |         |
| Highest HIV pVL (log<sub>10</sub>)    | 4.9 [4.3–5.4]   | –             |         |
| Duration of aviremia, y                | 11.4 [7.8–13.6] | – |         |
| Duration of aviremia & CD4+ T-cell count ≥350 cells/μL, y | 10.8 [7.8–13.0] | – |         |

(Continued)
Our results agree with those of two studies [5,24] that had included long-term, cART-treated, immunovirologically well-controlled HIV+ individuals. However, our results (versus [5] or [24], respectively) extend their findings because our population is more homogenous, facilitating exploration of the impact of: (1) longer-known HIV infection (median 20 [range 11–30] versus median 15 [range 1–27] or mean 15 [range 1–30] years), (2) longer cART exposure (median 17 [range 6–22] versus median 12 [range 1–21] years or unavailable), (3) more prolonged pVL undetectability (median 11 [range 5–17] versus median 10 [range 0–15] years or unavailable), (4) less severe immunosuppression (CD4+ T-count nadir median 249 [range 158–350] versus median 180 [range 0–620] and mean 172 [range 1–552] cells/μL) and (5) well-sustained immunovirological variables (duration of pVL undetectability and CD4+ T-cell counts >350 μL (median 11 [range 5–17] years versus unavailable for both studies; CD4/CD8 T-cell ratio (median 0.95 [range 0.67–1.10] versus median 0.75 [range 0.29–4.13] or unavailable).

According to Invernizzi et al. [24], the GCL was thinner only for the subgroup of cART-treated PLHIVs with a mean MoCA score <26/30 (n = 34) compared to HUCs. For PLHIVs with a MoCA score ≥26/30 (n = 35), GCL thickness was comparable to that of HUCs, as we found. As for Invernizzi et al. [24], the MoCA score was neither an inclusion nor exclusion criterion for our study. Only one of our PLHIVs had a MoCA score <26/30 (i.e., 25/30), probably because they met the parameters associated with the most preserved cognitive functions, i.e.: high educational level, CD4+ T-cell count nadir >200 cells/μL and current CD4/CD8 T-cell ratio ~1 [35–41].

Significant overall pRNFL thinning was found in other studies, but affected only PLHIVs with CD4+ T-cell count nadirs <100 cells/μL for ≥6 months, compared to PLHIVs with nadirs >100 cells/μL [21,22] or HUCs [21,23]. However, many HIV variables were missing in those reports: (1) HIV-seropositivity duration [22,23,42–44], (2) cART duration [22–24,44,45], (3) current pVL or duration of undetectability [21–23,42–43,46] and (4) current CD4+ T-cell counts [22,23,43,45]. Hence, those studies’ results cannot explain whether the pRNFL thinning could be attributed to severe immunodeficiency alone or its combination with prolonged HIV infection without sustained immunovirological control.

The higher frequency of CVSD-surrogate WMHs in aviremic, cART-treated PLHIVs compared to HUCs, not related to any ART classes, was recently reported [10,47]. We found only a trend toward significance for WMHs of presumed vascular origin between PLHIVs and HUC (p = 0.06). That failure to reach significance is probably due to a lack of statistical power of our study. These vascular abnormalities were associated with thinner overall pRNFLs, smaller total retina macular volumes and smaller CGL macular volumes, independently of HIV status. A
pRNFL thinning or defect was reported previously for the arteriosclerotic CSVD form [26] and cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) [48], a genetic form of CSVD. To the best of our knowledge, that association has not been reported previously in adult, cART-treated PLHIVs with CSVD. CSVD is

Table 3. Spectral domain-optical coherence tomography or visual function measurements and ocular findings of PLHIV and HUC participants.

| Parameter                        | PLHIVs (n = 56) | HUCs (n = 56) | p value |
|----------------------------------|-----------------|---------------|---------|
| Structural, mean±SD              |                 |               |         |
| pRNFL thickness, (μm)            |                 |               |         |
| Overall pRNFL                    | 99.5±9.6        | 99.6±8.3      | 0.97b   |
| Nasal                            | 75.9±15.2       | 75.6±15.2     | 0.82c   |
| Inferior                         | 128.9±14.5      | 130.2±14.5    |         |
| Temporal                         | 70.7±11.5       | 68.9±11.5     |         |
| Superior                         | 121.4±14.8      | 123.8±14.8    |         |
| Macula, mean±SD                  |                 |               |         |
| EDTRS total macular volume (mm³) | 8.7±0.4         | 8.6±0.4       | 0.52b   |
| EDTRS GCL volume (mm³)           | 0.95±0.099      | 0.93±0.115    | 0.32b   |
| EDTRS GCL thickness (μm)         |                 |               |         |
| Fovea                            | 17.6±6.6        | 15.8±6.6      | 0.31c   |
| Parafovea superior               | 48.3±8.0        | 46.5±8.0      |         |
| Parafovea nasal                  | 46.5±9.1        | 46.7±9.1      |         |
| Perifovea superior               | 33.3±4.3        | 32.7±4.3      |         |
| Perifovea temporal               | 28.7±3.2        | 27.9±3.2      |         |
| Perifovea inferior               | 31.1±4.1        | 30.6±4.1      |         |
| Perifovea nasal                  | 27.4±3.0        | 27.2±3.0      |         |
| Choroidal thickness (μm)         | 330±99          | 306±96        | 0.19b   |
| Functional, mean±SD              |                 |               |         |
| High-contrast VA EDTRS score     | 87.1±4.5        | 87.7±5.2      | 0.5b    |
| 2.5% low-contrast VA EDTRS score | 22.8±6.6        | 24.2±8.6      | 0.34a   |
| VF foveal threshold (dB)         | 37.0±1.7        | 37.1±1.5      | 0.73b   |
| VF mean deviation (dB)           | −1.34±1.68      | −0.33±1.46    | <0.001b |
| VF pattern standard deviation (dB)| 2.02±0.98       | 1.84±0.64     | 0.26c   |
| Color vision (total errors score)| 16.37±2.71      | 16.41±4.86    | 0.96b   |
| Color vision (C-index)           | 1.59±0.31       | 1.57±0.52     | 0.87b   |
| Ocular features, mean±SD         |                 |               |         |
| Axial length (mm)                | 23.75±0.83      | 23.82±0.74    | 0.66b   |
| Spherical equivalent refraction (diopter) | 0.35±1.03 | 0.14±1.02 | 0.27b |
| Objective scattering index       | 0.77±0.52       | 0.82±0.73     | 0.73b   |
| Intraocular pressure (mm Hg)     | 13.9±2.8        | 15.1±2.8      | 0.02c   |

a Overall pRNFL thickness is the average of the four quadrants.
b Mann-Whitney U-test.
c Between-group [PLHIVs vs. HUCs] ANOVA on repeated measures (pRNFL quadrants and GCL ETDRS-grid subfields). PLHIVs: human immunodeficiency virus-infected participants; HUCs: HIV-uninfected controls; HIV: human immunodeficiency virus; pRNFL: peripapillary retinal nerve-fiber layer; SD: standard deviation; EDTRS: Early Treatment Diabetic Retinopathy Study; GCL: ganglion-cell layer; VA: visual acuity; dB: decibels; VF: visual field; C-index: color confusion index; mm Hg: millimeters of mercury.

https://doi.org/10.1371/journal.pone.0229977.t003
characterized by thickening of the walls of the small perforating arteries in the brain, resulting in low cerebral blood flow [49]. A causative role of cerebral hypoperfusion and decreased perfusion of the inner retinal layers has been advanced to explain the association of CSVD with pRNFL and GCL thinning, as shown for CADASIL [50]. Our results agree with an emerging change of the NeuroHIV paradigm, highlighting the potential contribution of vascular brain damage in aging PLHIVs [16].

Despite being the first combined OCT–MRI study in middle-aged, cART-treated PLHIVs with well-sustained immune restoration, our study might suffer from a lack statistical power. Although our study-sample size might be considered relatively small, it is in accordance with previous similar publications (Table 1) and is sufficient to highlight pRNFL differences in these subjects. Although PLHIV and HUC pRNFL-thickness sameness cannot be established, our study’s statistical power to detect thinning of −5 μm was 90%. Interestingly, the test–retest variability of SD-OCT–measured pRNFL thickness was −5 μm [51]. Because the primary endpoint and the power calculation were based on the overall pRNFL thickness, interpretation of the lack of a smaller GCL volume and localized pRNFL thinning in our study requires prudence. Localized pRNFL thinning could result from methodological biases secondary to the multiplicity of statistical comparisons without control for inflation of the type-1 error [52]. That bias was also seen in macula studies, in which multiple quadrants and multiple retinal

Table 4. Associations between structural measurements and other variables of PLHIVs and/or HUCs.

| Analysis (predictor variables) | Overall pRNFL thickness | Temporal pRNFL thickness | Total retina macular volume | GCL macular volume |
|-------------------------------|-------------------------|--------------------------|-----------------------------|-------------------|
|                               | β  | p    | β  | p    | β  | p    | β  | p    |
| PLHIVs and HUCs (HIV+/-)      |    |      |    |      |    |      |    |      |
| High-contrast VA EDTRS score   | 0.43 μm/letter | 0.01 | 0.13 μm/letter | 0.57 | 0.02 mm³/letter | 0.04 | 0.004 mm³/letter | 0.03 |
| HIV+/- interaction            | 0.84 | HIV+/- interaction | 0.38 | HIV+/- interaction | 0.41 | HIV+/- interaction | 0.21 |
| 2.5% low-contrast VA EDTRS score | 0.10 μm/letter | 0.36 | 0.18 μm/letter | 0.21 | 0.01 mm³/letter | 0.07 | 0.002 mm³/letter | 0.13 |
| HIV+/- interaction            | 0.97 | HIV+/- interaction | 0.30 | HIV+/- interaction | 0.34 | HIV+/- interaction | 0.17 |
| VF mean deviation             | 0.78 μm/DB | 0.15 | 0.37 μm/DB | 0.60 | 0.00 mm³/DB | 0.93 | −0.001 mm³/DB | 0.83 |
| HIV+/- interaction            | 0.68 | HIV+/- interaction | 0.33 | HIV+/- interaction | 0.53 | HIV+/- interaction | 0.38 |
| Color vision C-index          | 0.5 μm/U | 0.82 | 0.69 μm/U | 0.79 | −0.04 mm³/U | 0.69 | 0.020 mm³/U | 0.41 |
| HIV+/- interaction            | 0.97 | HIV+/- interaction | 0.59 | HIV+/- interaction | 0.47 | HIV+/- interaction | 0.36 |
| Axial length                  | −4.45 μm/mm | <0.001 | 1.55 μm/mm | 0.27 | −0.12 mm³/mm | 0.02 | −0.021 mm³/mm | 0.11 |
| HIV+/- interaction            | 0.83 | HIV+/- interaction | 0.37 | HIV+/- interaction | 0.55 | HIV+/- interaction | 0.35 |
| Age                           | −0.21 μm/year | 0.007 | −0.14 μm/year | 0.16 | −0.02 mm³/year | <0.001 | −0.003 mm³/year | <0.001 |
| HIV+/- interaction            | 0.99 | HIV+/- interaction | 0.38 | HIV+/- interaction | 0.44 | HIV+/- interaction | 0.28 |
| PLHIVs                        |     |      |    |      |    |      |    |      |
| Duration of HIV seropositivity | −0.46 μm/year | 0.07 | −0.28 μm/year | 0.33 | −0.01 mm³/year | 0.23 | −0.002 mm³/year | 0.16 |
| CD4+ T-cell count nadir, cells/μL | 0.08 μm/(cells/μL) | 0.40 | 0.001 μm/(cells/μL) | 0.90 | 0.00 mm³/(cells/μL) | 0.25 | 0.000 mm³/(cells/μL) | 0.09 |

a Overall pRNFL thickness is the average of the four quadrants.

b Linear-regression models including HIV status.

c Multivariable linear-regression analysis using age and duration of HIV seropositivity.

d Univariate linear-regression analysis.

e Thickness unit/(nadir unit in cells/μL).

PLHIVs: persons living with human immunodeficiency virus-infected; HUCs: HIV-uninfected controls; HIV: human immunodeficiency virus; pRNFL: peripapillary retinal nerve-fiber layer; EDTRS: Early Treatment Diabetic Retinopathy Study; GCL: ganglion-cell layer; VA: visual acuity; dB: decibels; VF: visual field; C-index: color confusion index.

https://doi.org/10.1371/journal.pone.0229977.t004

https://doi.org/10.1371/journal.pone.0229977.t004
Fig 1. Association between overall peripapillary retinal nerve-fiber-layer (pRNFL) thickness (top) or ganglion-cell-layer (GCL) volume (bottom) and age of PLHIVs and HUCs. Significant linear correlations were found between the overall pRNFL or macular GCL volume and the ages of the persons living with human immunodeficiency virus (PLHIVs) or the HIV-uninfected controls (HUCs). The HIV status had no significant effect on this association. The linear-regression equation is given.

https://doi.org/10.1371/journal.pone.0229977.g001
Fig 2. No association between PLHIVs’ overall peripapillary retinal nerve-fiber-layer (pRNFL) thickness (top) or ganglion-cell-layer (GCL) volume (bottom) and CD4+ T-cell count nadirs of the persons living with human immunodeficiency virus (PLHIVs). The vertical line represents the CD4+ T-cell count nadir of 100 cells/μL, because previous studies found that only PLHIVs with nadirs <100 cells/μL were more likely to have thinner pRNFLs. In our study only nine PLHIVs had a nadir <100 cells/μL but their pRNFL thicknesses and macular GCL volumes did not differ from those of the other PLHIVs.

https://doi.org/10.1371/journal.pone.0229977.g002
Fig 3. Effect of cerebral small-vessel disease (CSVD) on overall peripapillary retinal nerve-fiber-layer (pRNFL) thickness (top) and ganglion-cell-layer (GCL) volume (bottom) in all participants. The mean overall pRNFL thickness (top) and the mean macular GCL volume (bottom) are reported for all participants, persons living with human immunodeficiency virus (PLHIVs) and for HIV-uninfected controls (HUCs). Error bars represent the standard deviation. Participants with MRI-defined CSVD had significantly thinner pRNFL (p = 0.04; ANOVA) and smaller macular GCL volume (p<0.01; ANOVA) compared to the participants with no CSVD. HIV status had no significant effect on pRNFL and no significant interaction with the effect of CSVD on pRNFL (S2 Table).

https://doi.org/10.1371/journal.pone.0229977.g003
layer thicknesses generated high numbers of p values. Such methodological biases were previously highlighted by Demirkaya et al. [5].

Although our series is not representative of the entire HIV+ population, it is representative of PLHIVs receiving care in northern Europe, where >90% are successfully treated [53]. However, the 2019 UNAIDS world epidemiological data showed that 79% of PLHIVs are aware of their seropositivity, 78% of PLHIVs knowing their HIV status are cART-treated and 86% of those cART-treated PLHIVs have a pVL below the detection threshold (unaid.org). Moreover, it was recently demonstrated that low pVLs of 51–200 copies/mL were strongly associated with virological failure [54]. Thus, HIV-induced brain damage may be more a legacy effect resulting from prior incomplete virus control [54,55]. Those findings provide support for the European definition of virological failure as persistent pVLs of >50 copies/mL (eacso-ciety.org). Our findings should not be compared or held as a contradiction to historical studies and may better apply to future PLHIV cohorts, for whom the therapeutic guidelines recommend that cART must be initiated for a CD4+ T-cell count threshold ≥500 cells/μL [56]. Indeed, the CASCADE study showed that PLHIVs are mostly diagnosed and treated with a CD4+ T-cell count nadir >200 cells/μL [57]. Recent findings showed that full viral suppression may preserve long-term PLHIVs’ brain health [58]. Hence, continuing to report results concerning virologically uncontrolled, cART-treated PLHIVs is not really suitable [54,55,58].

In addition to the OCT evaluation of visual pathway structures, most visual evaluation and ocular parameters were similar for PLHIVs and HUCs, with the exception of visual field MDs and IOP. Decreased visual field MD is a classic sign of HIV–NRD but in our study it cannot be explained by pRNFL thinning or decreased GCL macular volume. That decline could however be explained by functional changes without structural damage of the retinal ganglion cells or other cells implicated in vision. Indeed, decreased cone-photoreceptor density in HIV+ participants was found using an adaptive optics camera [59] and SD-OCT visualized possible changes in retinal layers other than GCL and RNFL [5,60,61]. Lower IOP in HIV+ participants was previously described and its causes are more likely multifactorial [61]. Our results showed that this diminished IOP persists in PLHIVs with long-term, well-sustained immune control.

Our results showed that cART-treated PLHIVs who successfully achieved sustained immunovirological control, even with HIV infection lasting 20 years, do not have pRNFL thinning. That is an optimistic finding in terms of PLHIVs aging. However, in line with recent results from a study on HIV-infected children [28], as in the general population, CSVD in our middle-aged PLHIVs was associated with thinner pRNFLs and GCLs.

**Supporting information**

S1 Fig. The 9 Early Treatment Diabetic Retinopathy Study (ETDRS)-grid subfields used to analyze ganglion-cell layer thickness in right and left eyes. 1, fovea; 2, parafovea superior; 3, parafovea temporal; 4, parafovea inferior; 5, parafovea nasal; 6, perifovea superior; 7, perifovea temporal; 8, perifovea inferior; and 9, perifovea nasal.  
(JPG)

S1 Table. Associations between radiological and spectral-domain optical coherence tomography findings and HIV status. 
(DOCX)

S2 Table. Optical coherence tomography measurements in PLHIVs and HUCs using the other eye when both eyes were assessable. PLHIVs, persons living with HIV; HUCs, healthy uninfected controls.  
(DOCX)
S1 File. Excel file containing all the relevant data underlying the findings described in the manuscript. (XLSX)

Acknowledgments

The authors thank Janet Jacobson for editorial assistance and Gilbert Lesage for bibliographic assistance.

Author Contributions

Conceptualization: Cedric Lamirel, Antoine Moulignier.
Data curation: Cedric Lamirel, Antoine Moulignier.
Formal analysis: Cedric Lamirel, Antoine Moulignier.
Funding acquisition: Cedric Lamirel, Laurence Salomon.
Investigation: Cedric Lamirel, Nadia Valin, Julien Savatovsky, François-Xavier Lescure, Anne-Sophie Alonso, Philippe Girard, Jean-Paul Vincensini, Pierre-Marie Girard, Isabelle Cochereau, Antoine Moulignier.
Methodology: Laurence Salomon, Antoine Moulignier.
Project administration: Cedric Lamirel, Laurence Salomon, Antoine Moulignier.
Resources: Cedric Lamirel.
Software: Cedric Lamirel.
Supervision: Cedric Lamirel, Laurence Salomon, Antoine Moulignier.
Validation: Cedric Lamirel, Laurence Salomon, Antoine Moulignier.
Visualization: Cedric Lamirel, Antoine Moulignier.
Writing – original draft: Cedric Lamirel, Antoine Moulignier.
Writing – review & editing: Cedric Lamirel, Nadia Valin, François-Xavier Lescure, Pierre-Marie Girard, Laurence Salomon, Isabelle Cochereau, Antoine Moulignier.

References

1. Costagliola D. Demographics of HIV and aging: Curr Opin HIV AIDS. 2014; 9:294–301. https://doi.org/10.1097/COH.000000000000076 PMID: 24824889
2. Ghosn J, Taiwo B, Seedat S, Autran B, Katlama C. HIV. The Lancet. 2018; 392:685–697. https://doi.org/10.1016/S0140-6736(18)31311-4
3. Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014; 9: 552–558. https://doi.org/10.1097/COH.0000000000000108 PMID: 25203642
4. Mzingwane ML, Tiemessen CT. Mechanisms of HIV persistence in HIV reservoirs. Rev Med Virol. 2017; 27. https://doi.org/10.1002/rmv.1924 PMID: 28128885
5. Demirkaya N, Wit FWNM, van Den Berg TJTP, Kooij KW, Prins M, Schlingemann RO, et al. HIV-Associated Neuroretinal Disorder in Patients With Well-Suppressed HIV-Infection: A Comparative Cohort Study. Investig Ophthalmology Vis Sci. 2016; 57: 1388. https://doi.org/10.1167/iovs.15-18537 PMID: 27018641
6. Small RC, Brew BJ. HIV-associated neurocognitive disorder. Handbook of Clinical Neurology. Elsevier; 2018. pp. 75–97.
7. Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M. Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol. 2015; 24:279–282. https://doi.org/10.1016/j.carpath.2015.07.001 PMID: 26233281

8. Cohen RA, Seider TR, Navia B. HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimers Res Ther. 2015; 7. https://doi.org/10.1186/s13195-015-0123-4 PMID: 25848401

9. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12:822–838. https://doi.org/10.1016/S1474-4422(13)70124-8 PMID: 23867200

10. Moulignier A, Savatovsky J, Assoumou L, Lescure F-X, Lamirel C, Godin O, et al. Silent cerebral small-vessel disease is twice as prevalent in middle-aged individuals with well-controlled, combination antiretroviral therapy-treated human immunodeficiency virus (HIV) than in HIV-uninfected individuals. Clin Infect Dis. 2018; 66:1762–1769. https://doi.org/10.1093/cid/cix1075 PMID: 29244126

11. Wardlaw JM, Smith C, Dichtgens M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019; 18: 684–696. https://doi.org/10.1016/S1474-4422(19)30079-1 PMID: 31097385

12. Su T, Wit FWNM, Caan MWA, Schouten J, Prins M, Geurtsen GJ, et al. White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy: AIDS. 2016; 30:2329–2339. https://doi.org/10.1097/QAD.0000000000001133 PMID: 27149087

13. van Zoest RA, Underwood J, De Francesco D, Sabin CA, Cole JH, Wit FW, et al. Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers. J Infect Dis. 2018; 217:69–81. https://doi.org/10.1093/infdis/jjx553 PMID: 29069436

14. Schouten J, Su T, Wit FW, Kootstra NA, Caan MWA, Geurtsen GJ, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS. 2016; 30:1027–1038. https://doi.org/10.1097/QAD.0000000000001017 PMID: 26752277

15. Watson C, Busovaca E, Foley JM, Allen IE, Schwarz CG, Jahanshad N, et al. White matter hyperintensities correlate to cognition and fiber tract integrity in older adults with HIV. J Neurovirol. 2017; 23:422–429. https://doi.org/10.1007/s13365-016-0509-5 PMID: 28101804

16. Cysique LA, Brew BJ. Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm. J Neurovirol. 2019; 25:710–721. https://doi.org/10.1007/s13365-018-0706-5 PMID: 30635846

17. Cameron JR, Tatham AJ. A window to beyond the orbit: the value of optical coherence tomography in non-ocular disease. Acta Ophthalmol (Copenh). 2016;533–539. https://doi.org/10.1111/aos.12978 PMID: 26803923

18. Kwa VI, van der Sande JJ, Stam J, Tijmes N, Vrooland JL. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002; 59:1536–1540. https://doi.org/10.1212/01.wnl.000033093.16450.5c PMID: 12451193

19. Blumenthal EZ, Parikh RS, Pe’er J, Naik M, Kaliner E, Cohen MJ, et al. Retinal nerve fibre layer imaging compared with histological measurements in a human eye. Eye. 2009; 23:171–175. https://doi.org/10.1038/sj.eye.6702942 PMID: 17721504

20. Lamirel C, Newman N, Biousse V. The use of optical coherence tomography in neurology. Rev Neurol (Paris). 2009; 6:1038–1106. PMID: 20065921

21. Faria e Arantes TE, Garcia CR, Mello PA de A, Muccioi C. Structural and functional assessment in HIV-infected patients using optical coherence tomography and frequency-doubling technology perimetry. Am J Ophthalmol. 2010; 149:571–576.e2. https://doi.org/10.1016/j.ajo.2009.11.026 PMID: 20149340

22. Cheng S, Klein H, Bartsch D-U, Kozak I, Marcotte TD, Freeman WR. Relationship between retinal nerve fiber layer thickness and driving ability in patients with human immunodeficiency virus infection. Graefes Arch Clin Exp Ophthalmol. 2011; 249:1643–1647. https://doi.org/10.1007/s00417-011-1735-4 PMID: 21732109

23. Kozak I, Bartsch D-U, Cheng L, Kosobucki BR, Freeman WR. Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT. Am J Ophthalmol. 2005; 139:295–301. https://doi.org/10.1016/j.ajo.2004.09.039 PMID: 15733991

24. Invernizzi A, Acquastapace A, Bochichio S, Resnati C, Rusconi S, Ferrari M, et al. Correlation between inner retinal layer thickness and cognitive function in HIV: new insights from an exploratory study. AIDS. 2018; 32:1485–1490. https://doi.org/10.1097/QAD.0000000000001850 PMID: 29734219

25. Costello F, Burton JM. Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis? Eye Brain. 2018; 10: 7–63. https://doi.org/10.2147/EB.S139417 PMID: 30104912

26. Kim M, Park KH, Kwon JW, Jeoung JW, Kim T-W, Kim DM. Retinal Nerve Fiber Layer Defect and Cerebral Small Vessel Disease. Investig Ophthalmology Vis Sci. 2011; 52: 6882. https://doi.org/10.1167/iovs.11-7276 PMID: 21791593
27. Ulusoy MO, Horasanli B, Kal A. Retinal vascular density evaluation of migraine patients with and without aura and association with white matter hyperintensities. Acta Neurol Belg. 2019 [cited 22 Mar 2019]. https://doi.org/10.1007/s13760-019-01094-7 PMID: 30762208

28. Blokhuis C, Demirkaya N, Cohen S, Wit FWMN, Scherpier HJ, Reiss P, et al. The eye as a window to the brain: neuroretinal thickness is associated with microstructural white matter injury in HIV-infected children. Invest Ophthalmol Vis Sci. 2016; 57:3864. https://doi.org/10.1167/iovs.16-19716 PMID: 27447087

29. Sonka M, Abràmoff MD. Quantitative analysis of retinal OCT. Med Image Anal. 2016; 33:165–169. https://doi.org/10.1016/j.media.2016.06.001 PMID: 27503080

30. Garvin MK, Abramoff MD, Xiaodong Wu, Russell SR, Burns TL, Sonka M. Automated 3-D Intra-retinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans Med Imaging. 2009; 28:1436–1447. https://doi.org/10.1109/TMI.2009.2016958 PMID: 19278927

31. Abramoff MD, Garvin MK, Sonka M. Retinal imaging and image analysis. IEEE Rev Biomed Eng. 2010; 3: 169–208. https://doi.org/10.1109/RBME.2010.2084657 PMID: 22275207

32. Fazel PL, Casaletto KB, Paolillo E, Moore RC, Moore DJ, The Hnrp Group null. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning. J Clin Exp Neuropsychol. 2017; 39: 842–853. https://doi.org/10.1080/13803395.2016.1273319 PMID: 28122474

33. Chartier M, Crouch P-C, Tullis V, Catella S, Frawley E, Filanosky C, et al. The Montreal Cognitive Assessment: a pilot study of a brief screening tool for mild and moderate cognitive impairment in HIV-positive veterans. J Int Assoc Provid AIDS Care. 2015; 14:197–201. https://doi.org/10.1177/2325974144557270 PMID: 25487428

34. Alasil T, Wang K, Keane PA, Lee H, Baniasadi N, de Boer JF, et al. Analysis of normal retinal nerve fiber layer thickness by age, sex, and race using spectral domain optical coherence tomography. J Glaucoma. 2013; 22:532–541. https://doi.org/10.1097/IJG.0b013e318255bb4a PMID: 22549477

35. Foley JM, Ettenhofer ML, Kim MS, Behdin N, Castellon SA, Hinkin CH. Cognitive reserve as a protective factor in older HIV-positive patients at risk for cognitive decline. Appl Neuropsychol Adult. 2012; 19:16–25. https://doi.org/10.1080/09084282.2011.595601 PMID: 22385375

36. Crum-Cianflone NF, Moore DJ, Letendre S, Roediger MP, Eberly L, Weintrob A, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013; 80: 371–379. https://doi.org/10.1212/01.WNL.0000377522.94788.82 PMID: 17914066

37. Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, et al. Virolologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation: The CD4:CD8 ratio and neurocognitive disorders. HIV Med. 2015; 16:431–440. https://doi.org/10.1111/hiv.12246 PMID: 25961452

38. Cole MA, Margolick JB, Cox C, Li X, Selnes OA, Martin EM, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007; 69: 2213–2220. https://doi.org/10.1212/01.WNL.0000277522.94788.82 PMID: 17914066

39. Cole JH, Caan MWA, Underwood J, De Francesco D, van Zoest RA, Wit FWMN, et al. No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus: longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) project. Clin Infect Dis. 2018; 66: 1899–1909. https://doi.org/10.1093/cid/cix1124 PMID: 29309532

40. Pedersen KK, Pedersen M, Gaardbo JC, Ronit A, Hartling HJ, Bruuns gaard H, et al. Persisting inflammation and chronic immune activation but intact cognitive function in HIV-infected patients after long-term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2013; 63:272–279. https://doi.org/10.1097/QAI.0b013e318289bced PMID: 23392469

41. Ellis RJ, Badiée J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011; 25: 1747–1751. https://doi.org/10.1097/QAD.0b013e32834a40cd PMID: 21750419

42. Demirkaya N, Wit F, Schlingemann R, Verbraak F. Neuroretinal degeneration in HIV patients without opportunistic ocular infections in the CART era. AIDS Patient Care STDs. 2010; 24: 323–328. https://doi.org/10.1089/apc.2010.0091 PMID: 20988022

43. Pathai S, Lawn SD, Weiss HA, Cook C, Bekker L-G, Gilbert CE. Retinal nerve fibre layer thickness and contrast sensitivity in HIV-infected individuals in South Africa: a case-control study. PLoS ONE. 2013; 8: e73694. https://doi.org/10.1371/journal.pone.0073694 PMID: 24069225

44. Bartsch D-U, Kozak I, Grant I, Knudsen VL, Weinreb RN, Lee BR, et al. Retinal nerve fiber and optic disc morphology in patients with human immunodeficiency virus using the Heidelberg retina tomography 3. PLOS ONE. 2015; 10: e0133144. https://doi.org/10.1371/journal.pone.0133144 PMID: 26258547
45. Barteselli G, Chhablani J, Gomez ML, Doede AL, Dustin L, Kozak I, et al. Visual function assessment in simulated real-life situations in HIV-infected subjects. PLoS ONE. 2014; 9: e97023. https://doi.org/10.1371/journal.pone.0097023 PMID: 24809827

46. Arantes TE, Garcia CR, Tavares IM, Mello PA, Muccioli C. Relationship between retinal nerve fiber layer and visual field function in human immunodeficiency virus–infected patients without retinitis. Retina. 2012; 32:152–159. https://doi.org/10.1097/IAE.0b013e31821502e1 PMID: 21572092

47. Januel E, Godin O, Moulignier A, Lescure F-X, Savatovsky J, Lamirel C, et al. Impact of ART classes on the increasing risk of cerebral small- vessel disease in middle-aged, well-controlled, cART-treated, HIV-infected individuals. J Acquir Immune Defic Syndr. 2019; 81:547–551. https://doi.org/10.1097/QAI.0000000000002084 PMID: 31107300

48. Rufa A, Pretegiani E, Frezzotti P, De Stefano N, Cevenini G, Dotti MT, et al. Retinal nerve fiber layer thinning in CADASIL: an optical coherence tomography and MRI study. Cerebrovasc Dis. 2011; 31:77–82. https://doi.org/10.1159/000321339 PMID: 21051887

49. Shi Y, Thrippleton MJ, Makin SD, Marshall I, de Craen AJ, et al. Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016; 36:1653–1667. https://doi.org/10.1177/0271678X16662891 PMID: 27496552

50. Harju M, Tuominen S, Summanen P, Viitanen M, Pöyhönen M, Nikoskelainen E, et al. Scanning laser doppler flowmetry shows reduced retinal capillary blood flow in CADASIL. Stroke. 2004; 35: 2449–2452. https://doi.org/10.1161/01.STR.0000145048.94499.b9 PMID: 21572092

51. Tan BB, Natividad M, Chua K-C, Yip LW. Comparison of retinal nerve fiber layer measurement between 2 spectral domain OCT instruments: J Glaucoma. 2012; 21:266–273. https://doi.org/10.1097/IJG.0b013e3182071cdd PMID: 21637116

52. Huque MF, Sankoh AJ. A reviewer's perspective on multiple endpoint issues in clinical trials. J Biopharm Stat. 1997; 7:545–564. https://doi.org/10.1080/10543409708835206 PMID: 9358328

53. Mary-Krause M, Grabar S, Liever L, Abgrall S, Billaud E, Boue F, et al. Cohort profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol. 2014; 43:1425–1436. https://doi.org/10.1093/ije/dyu002 PMID: 24550249

54. Fleming J, Mathews WC, Rutstein RM, Aberg J, Somboonthi C, Cheever LW, et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019; 33: 2005–2012. https://doi.org/10.1097/QAD.0000000000002306 PMID: 31061737

55. Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, et al. Longitudinal trajectories of brain volume and cortical thickness in treated and untreated primary human immunodeficiency virus infection. Clin Infect Dis. 2018; 67:1697–1704. https://doi.org/10.1093/cid/ciy362 PMID: 29697762

56. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373:795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

57. Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy—The CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med. 2010; 7: e1000239. https://doi.org/10.1371/journal.pmed.1000239 PMID: 20186270

58. Sanford R, Fellows LK, Ances BM, Collins DL. Association of brain structure changes and cognitive function with combination antiretroviral therapy in HIV-positive individuals. JAMA Neurol. 2018; 75:72–79. https://doi.org/10.1001/jamaneurol.2017.3036 PMID: 29318178

59. Arcinue CA, Bartsch D-U, El-Emam SY, Ma F, Doede A, Sharpest L, et al. Retinal thickening and photoreceptor loss in HIV eyes without retinitis. PLOS ONE. 2015; 10: e0132996. https://doi.org/10.1371/journal.pone.0132996 PMID: 26244973

60. Cetin EN, Sayin Kutlu S, Parca O, Kutlu M, Pekel G. The thicknesses of choroid, macular segments, peripapillary retinal nerve fiber layer, and retinal vascular caliber in HIV-1-infected patients without infectious retinitis. Retina. 2019; 39:1416–1423. https://doi.org/10.1097/IAE.0000000000002146 PMID: 29528981

61. Young MT, Melvani RT, Khan FA, Braich PS, Bansal S. Association of intraocular pressure with human immunodeficiency virus. Am J Ophthalmol. 2017; 176:203–209. https://doi.org/10.1016/j.ajo.2017.01.021 PMID: 28147228